Jamila Louahed leads the Belgium Research and Development Organization of GSK Vaccine, covering discovery, early, and late development activities. She joined GSK in 2005, taking on roles of increasing responsibility in immunology, translational research, and biomarkers for patient stratification. She was heading the research and development of cancer immunotherapeutics from discovery to late clinical development. After heading the cancer vaccine program, she was appointed the Head of R&D for infectious vaccines in 2015. She is in charge of the therapeutic vaccine portfolio and is the site Head of the R&D site in Rixensart in Belgium. Before joining GSK, Jamila obtained her Ph.D. in immunology and molecular biology at Université Catholique de Louvain in Brussels and completed her post-doctoral training at Magainin Pharmaceuticals in Philadelphia. Her research has focused on the discovery and characterization of two cytokines (IL-9 and IL-22), as well as their role in cancer and chronic disorders. Following her post-doctoral training, Jamila held a senior researcher position at the Brussels branch of the Ludwig Institute for Cancer Research.
.svg)
